NFKB1 and breast carcinoma: The mechanisms by which doxorubicin activates NF-κB remain unclear, however previously studied mechanisms include activation via the IKK complex, PI3K dependent pathway, and c-Abl kinase activity in breast cancer cells [67, 68].